HONG KONG, November 10, 2025 /PRNewswire/ — Shanghai, November 10, 2025 – At the 8th China International Import Expo (CIIE), Sino Biopharmaceutical Limited (“Sino Biopharm“) And Shanghai MediTrust Health Technology Group Co., Ltd.ediTrust Health”) signed a strategic cooperation agreement. The two parties will carry out in-depth cooperation on innovative drugs and commercial insurance, jointly explore a new drug insurance integration model, and help more patients access high-quality and affordable drugs earlier.
Mr. Tse Hsin, Executive Director and Senior Vice President of Sino Biopharm, and Mr. Wang Rundong, President of MediTrust Health, attended the signing ceremony and delivered speeches. Mr. Li Zhigang, President of MediTrust Health, was present as a witness.
Mr. Tse Hsin pointed out that as a leading Chinese innovative pharmaceutical group, Sino Biopharm generates an annual revenue of around RMB 30 billion, ranks 38th among the world’s top 50 pharmaceutical companies, and has a portfolio of more than 120 innovative drugs. With changing demographics and deepening healthcare reforms, commercial health insurance has become a critical channel for innovative medicines to reach the market. This not only eases the pressure on public health insurance funds, but also fuels R&D investments, thereby promoting a sustainable industrial cycle.
He highlighted MediTrust Health’s role as a central platform connecting pharmaceutical companies, insurers and patients, giving it a unique advantage in promoting “pharmacare integration.” Both parties will further explore AI, data collaboration and innovative payment solutions to set new benchmarks for industry coordination.
Mr. Wang Rundong noted that MediTrust Health remains patient-centric, leveraging AI and data-driven multiple payment infrastructure to streamline the diagnosis-treatment-payment journey. “We view insurance as more than a reimbursement tool: it should be a bridge to better healthcare, ensuring patients facing serious illnesses have faster, more affordable access to treatment with greater peace of mind,” he said. The partnership aligns with the “Healthy China 2030” strategy, aiming to improve the accessibility of medicines and build a win-win ecosystem for the pharmaceutical and insurance sectors.
About Sino Biopharm
Sino Biopharm is a leading Chinese pharmaceutical company that continues to invest in oncology, hepatology, respiratory and surgery, exploring innovative therapies to improve patients’ lives. The company has strong manufacturing capabilities and broad access to patients throughout China. Sino Biopharm is committed to bringing innovation to address unmet healthcare needs globally.
For more information about Sino Biopharm, please visit: https://www.sinobiopharm.com/fr/
About MediTrust Health
MediTrust Health, as an innovative healthcare payment platform in China, is committed to transforming China’s healthcare payment system by addressing the financing and payment challenges faced by patients, health insurers and pharmaceutical companies. With our AI-powered technologies, we have augmented the healthcare payment ecosystem and achieved triple wins for all three stakeholders. Focusing on the needs of patients, insurers and pharmaceutical companies, we have developed two primary offerings: Smart Pharma Solution provides pharmaceutical companies with a comprehensive suite of commercialization solutions throughout the product lifecycle; Smart Insurance Solution enables health insurance innovation by providing end-to-end support to health insurers through our proprietary AI-based technologies and access to quality medical resources. Additionally, we also launched Care2Pay, an all-in-one user platform, which allows users to discover more payment solutions and perform direct billing transactions, thereby providing more comprehensive, quality and accessible healthcare to patients and their families. As of December 31, 2024, we had managed approximately 393 million commercial health insurance policies, among which our city supplementary insurance projects covered 160 cities, and achieved cumulative savings of RMB 6.7 billion in direct costs for patients.
More information can be found on the official website: https://www.meditrusthealth.com/fr
View original content to download multimedia:^ https://www.prnewswire.com/apac/news-releases/meditrust-health-and-sino-biopharm-sign-strategic-cooperation-agreement-at-ciie-2025-to-advance-drug-insurance-integration-new-model-302609833.html
SOURCE MediTrust Health
